{"entity":{"id":"2027","kind":"year","name":"2027 in oncology","aka":["2027"],"tldr":"Everything OnCo dates to 2027: 32 entries, 31 expected dates and 1 trial reported. Each line links to the record it was read from, so the year is a view of the corpus rather than a second copy of it.","summary":"32 dated entries in OnCo fall in 2027: 31 expected dates and 1 trial reported.\n\nOf those, 9 to the day, 8 to the month, 3 to the quarter and 12 to the year only. Most of the corpus dates a fact to the year, because that is what the source it was read from gives; regulatory events and the readout calendar are the parts that carry a full date.\n\nEverything on this page is generated from the other records. It holds no fact of its own, and it changes when they do.","asOf":"2026-09-25","links":[],"tags":[],"related":["2026","2028"],"cancers":[],"sections":[],"technologies":[],"targets":[],"drugs":[],"companies":[],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"dependsOn":[],"notes":["Generated from every dated field in the corpus, not written by hand. The groups and the fields behind them are listed in src/lib/year-groups.ts; the reader is src/lib/years.ts."],"year":2027,"events":[{"group":"expected","date":"2027","precision":"year","title":"ASCENT-05 / OptimICE-RD: sacituzumab govitecan + pembrolizumab, post-neoadjuvant residual TNBC","note":"Expected date. Event-driven iDFS endpoint in patients with residual disease after KEYNOTE-522-type therapy. Would be the first ADC in the curative TNBC setting.","from":"ascent-05","refs":["sacituzumab-govitecan","pembrolizumab","tnbc"]},{"group":"expected","date":"2027","precision":"year","title":"ASCENT-07: sacituzumab govitecan versus chemotherapy, first-line HR-positive HER2-negative metastatic breast cancer","note":"Expected date. Tests the ADC as the first chemotherapy after endocrine therapy. Timing is a registry-based estimate.","from":"sacituzumab-govitecan","refs":["gilead","breast-hr-positive","trop2"]},{"group":"expected","date":"2027","precision":"year","title":"FDA decision on the Galleri multi-cancer early detection test (premarket approval)","note":"Expected date. Follows the 23 September 2026 advisory committee. PMA decisions typically come months after the panel; no date has been announced.","from":"galleri","refs":["grail","mced","nhs-galleri"]},{"group":"expected","date":"2027","precision":"year","title":"HARMONi-3: ivonescimab plus chemotherapy versus pembrolizumab plus chemotherapy, first-line NSCLC","note":"Expected date. The first head-to-head test of the PD-1 x VEGF bispecific against pembrolizumab in a Western population.","from":"ivonescimab","refs":["summit-therapeutics","akeso","pembrolizumab","nsclc"]},{"group":"expected","date":"2027","precision":"year","title":"IDeate-Lung02: ifinatamab deruxtecan versus chemotherapy, relapsed small-cell lung cancer","note":"Expected date. Pivotal phase 3 for the B7-H3 ADC from the Merck and Daiichi Sankyo collaboration. Timing is a registry-based estimate.","from":"ifinatamab-deruxtecan","refs":["daiichi-sankyo","merck","sclc","b7h3"]},{"group":"expected","date":"2027","precision":"year","title":"Krascendo 1: divarasib versus sotorasib or adagrasib, previously treated KRAS G12C NSCLC","note":"Expected date. The first phase 3 comparing KRAS G12C inhibitors head to head. Timing is a registry-based estimate.","from":"divarasib","refs":["roche-genentech","sotorasib","adagrasib","kras"]},{"group":"expected","date":"2027","precision":"year","title":"Regulatory filings for intismeran autogene plus pembrolizumab in adjuvant melanoma (INTerpath-001)","note":"Expected date. The sponsors said filings would follow the positive topline result of August 2026 and the full data presentation. Timing is our estimate.","from":"intismeran-autogene","refs":["moderna","merck","pembrolizumab","melanoma"]},{"group":"expected","date":"2027","precision":"year","title":"REJOICE-Ovarian01: raludotatug deruxtecan in platinum-resistant ovarian cancer","note":"Expected date. Phase 2/3 for the CDH6 ADC. Timing is a registry-based estimate.","from":"raludotatug-deruxtecan","refs":["daiichi-sankyo","merck","ovarian","cdh6"]},{"group":"expected","date":"2027","precision":"year","title":"SUNRAY-01: olomorasib plus pembrolizumab, first-line KRAS G12C NSCLC","note":"Expected date. Phase 3 in first-line KRAS G12C-mutant NSCLC. Timing is a registry-based estimate.","from":"olomorasib","refs":["eli-lilly","pembrolizumab","kras","nsclc"]},{"group":"expected","date":"2027","precision":"year","title":"TROPION-Lung14: datopotamab deruxtecan plus osimertinib, first-line EGFR-mutant NSCLC","note":"Expected date. Would move the TROP2 ADC into the first-line EGFR-mutant setting on top of the standard TKI. Timing is a registry-based estimate.","from":"datopotamab-deruxtecan","refs":["astrazeneca","daiichi-sankyo","osimertinib","nsclc"]},{"group":"expected","date":"2027","precision":"year","title":"US regulatory decision on sacituzumab tirumotecan (sac-TMT): first indication","note":"Expected date. Merck holds a Commissioner's National Priority Voucher (July 2026) that promises a 1 to 2 month review once filed.","from":"sacituzumab-tirumotecan","refs":["merck","kelun-biotech"]},{"group":"trial","date":"2027","precision":"year","title":"MOUNTAINEER-03 reported","from":"mountaineer-03","refs":["colorectal","her2-amplified-colorectal","tucatinib","trastuzumab"]},{"group":"expected","date":"2027-01","precision":"month","title":"A Study to Assess the Dose, Adverse Events, and Change in Disease Activity of Livmoniplimab as an Intravenous (IV) Solution in Combination With Budigalimab as a...","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"nct06109272","refs":[]},{"group":"expected","date":"2027-01","precision":"month","title":"PREOPANC-3 primary completion: perioperative versus adjuvant modified FOLFIRINOX for resectable pancreatic cancer (378 estimated participants; active, not recru...","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["preopanc","folfirinox","neoadjuvant-adjuvant","idea-pdac-neoadjuvant-chemotherapy-for-all-resectable-disease"]},{"group":"expected","date":"2027-03-23","precision":"day","title":"DESTINY-PanTumor02 study completion (trastuzumab deruxtecan in HER2-expressing tumours including biliary)","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["destiny-pantumor02","trastuzumab-deruxtecan"]},{"group":"expected","date":"2027-04-02","precision":"day","title":"AACR Annual Meeting 2027, Orlando (2 to 7 April)","note":"Confirmed date. Early science and first-in-human data: next-generation ADC payloads, degraders, in vivo CAR-T.","from":"aacr","refs":[]},{"group":"expected","date":"2027-05-16","precision":"day","title":"TOPAZ-1 study completion on the registry (durvalumab plus gemcitabine-cisplatin, first line)","note":"Watch item on the Gallbladder cancer roadmap: from a chance finding at gallstone surgery to a disease with its own trials.","from":"gallbladder-cancer-roadmap","refs":["topaz-1","durvalumab"]},{"group":"expected","date":"2027-06","precision":"month","title":"ASCENT-05 / OptimICE-RD (AFT-65, GBG 119, NSABP B-63): primary completion","note":"Estimated primary completion date on ClinicalTrials.gov.","from":"ascent-05","refs":[]},{"group":"expected","date":"2027-06","precision":"month","title":"ASCENT-05 / OptimICE-RD primary completion: sacituzumab govitecan with pembrolizumab vs physician's choice for residual invasive disease after neoadjuvant thera...","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["ascent-05","sacituzumab-govitecan","pembrolizumab","rcb"]},{"group":"expected","date":"2027-06-04","precision":"day","title":"ASCO Annual Meeting 2027, Chicago (4 to 8 June)","note":"Confirmed date. Where most practice-changing phase 3 trials are first presented.","from":"asco","refs":[]},{"group":"expected","date":"2027-07","precision":"month","title":"PM8002 (PD-L1 and VEGF bispecific) plus nab-paclitaxel vs placebo plus nab-paclitaxel, first line: primary completion (392 estimated participants)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["nct06419621","nab-paclitaxel"]},{"group":"expected","date":"2027-07-28","precision":"day","title":"TROPION-Breast05 primary completion: datopotamab deruxtecan with or without durvalumab vs chemotherapy with pembrolizumab, first line, PD-L1-positive (625 estim...","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["tropion-breast05","datopotamab-deruxtecan","cps"]},{"group":"expected","date":"2027-08-05","precision":"day","title":"ECLIPSE (Shield) study completion on the registry","note":"Watch item on the ctDNA tests roadmap: from a curiosity in plasma to blood tests that decide treatment.","from":"ctdna-tests","refs":["eclipse-shield","shield"]},{"group":"expected","date":"2027-09","precision":"month","title":"Botensilimab and balstilimab in colorectal cancer, primary completion (234 participants, actual; active, not recruiting): the first randomised read on Fc-enhanc...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["botensilimab","balstilimab","idea-immunotherapy-mss-crc","idea-crc-mss-immunotherapy-by-biomarker-not-by-line"]},{"group":"expected","date":"2027-09-20","precision":"day","title":"TROPION-Breast03 primary completion: datopotamab deruxtecan with or without durvalumab vs investigator's choice for stage I to III disease without pathological...","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["tropion-breast03","datopotamab-deruxtecan","rcb"]},{"group":"expected","date":"2027-12","precision":"month","title":"BL-B01D1-307 / PANKU-Breast02 study completion (izalontamab brengitecan vs chemotherapy in pretreated disease; primary completion 13 January 2026, actual)","note":"Watch item on the Triple-negative breast cancer roadmap: from a remainder defined by three negative tests to immunotherapy, antibody-drug conjugates and the residual disease proble...","from":"tnbc-roadmap","refs":["bl-b01d1-307","izalontamab-brengitecan"]},{"group":"expected","date":"2027-12","precision":"month","title":"RASolute 302 study completion on the registry","note":"Watch item on the Pancreatic cancer roadmap: from Whipple's operation to gemcitabine, FOLFIRINOX, adjuvant chemotherapy, PARP inhibition, KRAS inhibition, vaccines and the surveill...","from":"pancreatic-roadmap","refs":["rasolute-302","daraxonrasib"]},{"group":"expected","date":"2027-12-28","precision":"day","title":"BREAKWATER study completion: encorafenib and cetuximab with or without chemotherapy in previously untreated BRAF V600E metastatic disease (841 participants, act...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["breakwater","encorafenib","cetuximab","braf-v600e-colorectal"]},{"group":"expected","date":"2027-12-31","precision":"day","title":"MOUNTAINEER-03 primary completion: tucatinib with trastuzumab and mFOLFOX6 against standard of care in first-line HER2-positive metastatic colorectal cancer (40...","note":"Watch item on the Colorectal cancer roadmap: from the adenoma-carcinoma sequence and the first screening trials to total mesorectal excision, oxaliplatin, RAS testing, immunotherap...","from":"colorectal-roadmap","refs":["mountaineer","tucatinib","trastuzumab","her2-amplified-colorectal"]},{"group":"expected","date":"2027-Q1","precision":"quarter","title":"RASolute 302: daraxonrasib vs chemotherapy, second-line metastatic pancreatic cancer","note":"Expected date. Fully enrolled; event-driven OS endpoint. Sponsor has guided to a readout in 2026 or 2027. The first pivotal test of a pan-RAS inhibitor.","from":"daraxonrasib","refs":["revolution-medicines","pancreatic","kras"]},{"group":"expected","date":"2027-Q2","precision":"quarter","title":"IZABRIGHT-Breast01: iza-bren vs chemotherapy, first-line TNBC (PD-(L)1 ineligible)","note":"Expected date. Global first-line trial of the EGFR×HER3 bispecific ADC; timing is an estimate from enrolment start (2025).","from":"izabright-breast01","refs":["izalontamab-brengitecan","tnbc"]},{"group":"expected","date":"2027-Q4","precision":"quarter","title":"TROPION-Breast03: Dato-DXd ± durvalumab, post-neoadjuvant residual TNBC","note":"Expected date. Registry estimated primary completion 20 September 2027; topline may lag.","from":"tropion-breast03","refs":["datopotamab-deruxtecan","durvalumab","tnbc"]}]},"route":"/years/2027/","neighbours":{"year":[{"id":"2026","kind":"year","name":"2026 in oncology","route":"/years/2026/"},{"id":"2028","kind":"year","name":"2028 in oncology","route":"/years/2028/"}]}}